Abstract:BackgroundPortal hypertension is a key complication of portal hypertension, which is responsible for the development of varices, ascites, bleeding, and hepatic encephalopathy, which, in turn, cause a high mortality and requirement for liver transplantation.AimThis review deals with the present day state-of-the-art preventative treatments of portal hypertension in cirrhosis according to disease stage. Two main disease stages are considered, compensated and decompensated cirrhosis, the first having good prognosis and being mostly asymptomatic, and the second being heralded by the appearance of bleeding or non-bleeding complications of portal hypertension.ResultsThe aim of treatment in compensated cirrhosis is preventing clinical decompensation, the more frequent event being ascites, followed by variceal bleeding and hepatic encephalopathy. Complications are mainly driven by an increase of hepatic vein pressure gradient (HVPG) to values ≥10 mmHg (defining the presence of Clinically Significant Portal Hypertension, CSPH). Before CSPH, the treatment is limited to etiologic treatment of cirrhosis and healthy life style (abstain from alcohol, avoid/correct obesity…). When CSPH is present, association of a non-selective beta-blocker (NSBB), including carvedilol should be considered. NSBBs are mandatory if moderate/large varices are present. Patients should also enter a screening program for hepatocellular carcinoma. In decompensated patients, the goal is to prevent further bleeding if the only manifestation of decompensation was a bleeding episode, but to prevent liver transplantation and death in the common scenario where patients have manifested first non-bleeding complications. Treatment is based on the same principles (healthy life style..) associated with administration of NSBBs in combination if possible with endoscopic band ligation if there has been variceal bleeding, and complemented with simvastatin administration (20-40 mg per day in Child–Pugh A/B, 10–20 mg in Child C). Recurrence shall be treated with TIPS. TIPS might be indicated earlier in patients with: 1) Difficult/refractory ascites, who are not the best candidates for NSBBs, 2) patients having bleed under NSBBs or showing no HVPG response (decrease in HVPG of at least 20% of baseline or to values equal or below 12 mmHg). Decompensated patients shall all be considered as potential candidates for liver transplantation.ConclusionTreatment of portal hypertension has markedly improved in recent years. The present day therapy is based on accurate risk stratification according to disease stage.

Subharmonic Aided Pressure Estimation in Portal Hypertension: A Noninvasive Ultrasound‐based Technique to Assess Portal Pressure Gradient

Noninvasive Assessment of Portal Hypertension by Ultrasonography

Application of Ultrasound Elastography in Assessing Portal Hypertension

Portal vein pressure estimation and portal hypertension discrimination based on subharmonic scattering of ultrasound contrast agent microbubbles

[Progress in the Research on Hemodynamics of Portal Hypertension].

The portal hypertension syndrome: etiology, classification, relevance, and animal models

Contrast‐Enhanced Sonography for Quantitative Assessment of Portal Hypertension in Patients with Liver Cirrhosis

A new computational fluid dynamics based noninvasive assessment of portacaval pressure gradient

Technique innovation of endoscopic ultrasound portal pressure gradient measurement using standard manometer set for portal hypertension assessment

Endoscopic ultrasound-guided portal pressure gradient measurement in managing portal hypertension

Su1227 EUS-GUIDED PORTAL PRESSURE GRADIENT IS CONSISTENT WITH HEPATIC VENOUS PRESSURE GRADIENT IN PATIENTS WITH HEPATIC SINUSOIDAL OBSTRUCTIVE SYNDROME

Subharmonic scattering of ultrasound contrast agent microbubbles may be an effective and promising tool for portal vein pressure estimation

Quantitative evaluation of portal pressure by contrast enhanced ultrasonography

Application of Hepatic Transit Time and Shear Wave Velocity in Assessing Portal Pressure in Patients with Cirrhotic Portal Hypertension

Correlation Between Portal Vein Pressure and Subharmonic Scattering Signals From SonoVue Microbubbles in Canines

MRI-based Liver Vascular Morphology and Surface Nodularity Quantification for Assessment of Portal Hypertension

Applied research of conventional ultrasound combining shear-wave elastography in posthepatitic cirrhosis patients with portal hypertension

Bibliometric-analysis visualization and review of non-invasive methods for monitoring and managing the portal hypertension

Portal hypertension in patients with nonalcoholic fatty liver disease: Current knowledge and challenges

Fluctuating Portal Velocity Tracing with Rhythmicity: Ultrasonic Differential Diagnosis and Clinical Significance.

Evaluation of portal hypertension in the cirrhotic patient: hepatic vein pressure gradient and beyond